ETON PHARMACEUTICALS INC (ETON:NASDAQ)
$23.54 -1.74 (-6.8829%)
Analysed ETON PHARMACEUTICALS INC (ETON:NASDAQ) News Sources
How The Hemangeol Deal Is Reframing The Eton Pharmaceuticals (ETON) Investment Story
19-04-2026
yahoo.com
Eton Pharmaceuticals Announces CFO Succession Plan
16-04-2026
yahoo.com
April 2026's Top Growth Companies With Strong Insider Ownership
13-04-2026
yahoo.com
How The Eton Pharmaceuticals (ETON) Story Is Shifting With Hemangeol And New Valuation Targets
05-04-2026
yahoo.com
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
26-03-2026
yahoo.com
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
24-03-2026
yahoo.com
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
23-03-2026
yahoo.com
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
20-03-2026
yahoo.com
Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
20-03-2026
yahoo.com
Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
20-03-2026
moby.co
What is the current price of ETON PHARMACEUTICALS INC (ETON:NASDAQ)?
The current price of ETON PHARMACEUTICALS INC (ETON:NASDAQ) is $23.54.
ETON PHARMACEUTICALS INC (ETON:NASDAQ) absolute price change since previous trading day?
The absolute price change of ETON PHARMACEUTICALS INC (ETON:NASDAQ) since the previous trading day is $-1.74.
ETON PHARMACEUTICALS INC (ETON:NASDAQ) percentage price change since previous trading day?
The percentage price change of ETON PHARMACEUTICALS INC (ETON:NASDAQ) since the previous trading day is -6.8829%.
What is the most recent average sentiment score for ETON PHARMACEUTICALS INC (ETON:NASDAQ)?
The most recent average sentiment score for ETON PHARMACEUTICALS INC (ETON:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for ETON PHARMACEUTICALS INC (ETON:NASDAQ)?
The most recent sentiment for ETON PHARMACEUTICALS INC (ETON:NASDAQ) is .
SEC-8K** Filing Available For ETON PHARMACEUTICALS INC (ETON:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.